FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics and concerns an immunomodulator composition for treating bovine respiratory disease in cattle caused by Mannheimia haemolytica, which comprises a cationic liposome delivery vehicle and nucleic acid molecule, where nucleic acid molecule is a bacterially-derived non-coding DNA plasmid vector, produced in E.coli, containing 4242 base-pairs without a gene insert.
EFFECT: invention provides a eliciting systemic, non-specific and antigen-specific immune responses in animals for protection against infectious respiratory disease.
11 cl, 6 ex, 6 tbl, 27 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOSTIMULATING PLASMIDS | 2015 |
|
RU2740492C2 |
| VACCINE AGAINST RESPIRATORY DISEASE OF CATTLE | 2018 |
|
RU2762938C2 |
| BOVINE VIRAL DIARRHOEA VIRUS TYPE 1B VACCINE COMPOSITIONS AND METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2595873C2 |
| LIPOSOMAL ADJUVANT COMPOSITIONS | 2016 |
|
RU2736642C2 |
| ORAL VACCINE AGAINST RESPIRATORY DISEASE OF RUMINANTS CONTAINING POLYVINYLPYRROLIDONE | 2017 |
|
RU2761966C2 |
| METHOD OF BACTERINATION AGAINST INFECTION OF SPERMARIES BVDV | 2005 |
|
RU2335298C2 |
| INACTIVATED COMBINED VACCINE AGAINST INFECTIOUS RHINOTRACHEITIS, PARAFLU-3, RESPIRATORY SYNCYTIAL DISEASE, VIRAL DIARRHEA AND PASTEURELLOSIS OF CATTLE | 2009 |
|
RU2403061C1 |
| VACCINE AGAINST MANCHEMIOSIS, BIBERSHTEINIOSIS AND PASTERELOSIS OF LARGE AND SMALL CATTLE ASSOCIATED INACTIVATED, METHOD FOR ITS PREPARATION | 2020 |
|
RU2744744C1 |
| CATTLE DIARRHEA VIRUS WITH MODIFIED E PROTEIN | 2009 |
|
RU2524426C2 |
| LIQUID STABLE VACCINES CONTAINING BOVINE VIRUS | 2014 |
|
RU2723935C2 |
